Top

Published in:

01-08-2019 | Original Article

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Authors: Kirsti Aas, Sophie Dorothea Fosså, Rune Kvåle, Bjørn Møller, Tor Åge Myklebust, Ljiljana Vlatkovic, Stig Müller, Viktor Berge

Published in: World Journal of Urology | Issue 8/2019

Abstract

Purpose

To study the association between time from diagnosis to radical prostatectomy (RP-interval) and prostate cancer-specific mortality (PCSM), histological findings in the RP-specimen and failure after RP (RP-failure).

Methods

Patients diagnosed with non-metastatic prostate cancer (PCa) in 2001–2010 and prostatectomized within 180 days of biopsy were identified in the Cancer Registry of Norway and the Norwegian Prostate Cancer Registry. Patients were stratified according to risk groups and RP-intervals of 0–60, 61–90, 91–120 and 121–180 days. Aalen-Johansen and Kaplan–Meier methods estimated curves for PCSM, RP-failure and overall mortality. Multivariable Cox regressions and Chi-square tests were used to evaluate the impact of RP-interval on outcomes.

Results

In 5163 eligible patients, the median time from diagnosis to RP was 93 days (range 1–180). Risk group distribution was similar in all RP-interval groups. With almost eight years of observation, no association was found between RP-interval and PCSM in the intermediate-or high-risk groups. Increasing RP-interval did not increase the rate of adverse histological outcomes or incidence of RP-failure.

Conclusions

Increasing RP-interval up to 180 days was not associated with adverse oncological outcomes at eight years follow-up. These findings should be considered when planning for prostatectomy.

Available only for authorised users

Cancer Registry of Norway (2017) Annual Report 2016 with Results and Improvements from the Norwegian Prostate Cancer Registry. https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_prostatakreft.pdf. Accessed Oct 2018

Mottet N, Bellmunt J, Bolla M et al (2017) Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003 CrossRefPubMed

Neal RD, Tharmanathan P, France B et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92–S107. https://doi.org/10.1038/bjc.2015.48 CrossRefPubMedPubMedCentral

Bruins HM, Aben KK, Arends TJ, Heijden AG, Witjes AJ (2016) The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: a Netherlands Cancer Registry analysis. Urol Oncol 34(4):e161–e166. https://doi.org/10.1016/j.urolonc.2015.11.006 CrossRef

Jensen AR, Nellemann HM, Overgaard J (2007) Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 84(1):5–10. https://doi.org/10.1016/j.radonc.2007.04.001 CrossRefPubMed

Jooste V, Dejardin O, Bouvier V et al (2016) Pancreatic cancer: wait times from presentation to treatment and survival in a population-based study. Int J Cancer. 139(5):1073–1080. https://doi.org/10.1002/ijc.30166 CrossRefPubMed

Bourgade V, Drouin SJ, Yates DR et al (2014) Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol. 32(2):475–479. https://doi.org/10.1007/s00345-013-1045-z CrossRefPubMed

van den Bergh RC, Albertsen PC, Bangma CH et al (2013) Timing of curative treatment for prostate cancer: a systematic review. Eur Urol 64(2):204–215. https://doi.org/10.1016/j.eururo.2013.02.024 CrossRefPubMedPubMedCentral

Redaniel MT, Martin RM, Gillatt D, Wade J, Jeffreys M (2013) Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. BMC Cancer 13:559. https://doi.org/10.1186/1471-2407-13-559 CrossRefPubMedPubMedCentral

10.

O'Callaghan ME, Shi Z, Kopsaftis T, Moretti K (2017) Prostate cancer outcomes and delays in care. Int Urol Nephrol 49(3):449–455. https://doi.org/10.1007/s11255-017-1508-z CrossRefPubMed

11.

Morini MA, Muller RL, de Castro Junior PCB, de Souza RJ, Faria EF (2018) Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter? World J Urol 36(8):1225–1231. https://doi.org/10.1007/s00345-018-2251-5 CrossRefPubMed

12.

Berg WT, Danzig MR, Pak JS et al (2015) Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. Prostate 75(10):1085–1091. https://doi.org/10.1002/pros.22992 CrossRefPubMed

13.

Zanaty M, Alnazari M, Ajib K et al (2018) Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World J Urol 36(1):1–6. https://doi.org/10.1007/s00345-017-2105-6 CrossRefPubMed

14.

Seklehner S, Hladschik-Kermer B, Lusuardi L, Schabauer C, Riedl C, Engelhardt PF (2013) Psychological stress assessment of patients suffering from prostate cancer. Scand J Urol 47(2):101–107. https://doi.org/10.3109/00365599.2012.700946 CrossRefPubMed

15.

Hernes E, Kyrdalen A, Kvale R et al (2010) Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int. 105(6):805–811. https://doi.org/10.1111/j.1464-410X.2009.08834.xdiscussion 811 CrossRefPubMed

16.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242. https://www.ncbi.nlm.nih.gov/pubmed/16096414. Accessed Oct 2018CrossRefPubMed

17.

Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM (2012) Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int 110(2):211–216. https://doi.org/10.1111/j.1464-410X.2011.10666.x CrossRefPubMed

18.

Pompe RS, Davis-Bondarenko H, Zaffuto E et al (2017) Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation or no local treatment. Prostate. https://doi.org/10.1002/pros.23316 CrossRefPubMed

19.

Abdollah F, Schmitges J, Sun M et al (2012) Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 19(9):836–844. https://doi.org/10.1111/j.1442-2042.2012.03052.x CrossRefPubMed

20.

Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958. https://doi.org/10.1093/jnci/djq154 CrossRefPubMedPubMedCentral

21.

Aas K, Axcrona K, Kvale R et al (2017) Ten-year mortality in men with nonmetastatic prostate cancer in Norway. Urology 110:140–147. https://doi.org/10.1016/j.urology.2017.07.048 CrossRefPubMed

22.

Holmstrom B, Holmberg E, Egevad L et al (2010) Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 184(4):1322–1327. https://doi.org/10.1016/j.juro.2010.06.008 CrossRefPubMed

23.

Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220 CrossRefPubMed

24.

Vatne K, Stensvold A, Myklebust TA et al (2017) Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study. Acta Oncol. https://doi.org/10.1080/0284186X.2017.1314006 CrossRefPubMed

25.

Sun M, Abdollah F, Hansen J et al (2012) Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? J Sex Med 9(11):2961–2969. https://doi.org/10.1111/j.1743-6109.2012.02806.x CrossRefPubMed

26.

Kvale R, Moller B, Wahlqvist R et al (2009) Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103(12):1647–1654. https://doi.org/10.1111/j.1464-410X.2008.08255.x CrossRefPubMed

27.

Abern MR, Aronson WJ, Terris MK et al (2013) Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate 73(4):409–417. https://doi.org/10.1002/pros.22582 CrossRefPubMed

28.

Sundhedsstyrelsen (2016) Pakkeforløb for prostatakræft. https://www.sst.dk/da/sygdom-og-behandling/kraeft/pakkeforloeb/~/media/086DCAA5E5B14713BA08556124EB4681.ashx. Accessed Oct 2018

29.

Norwegian Directorate of Health (2016) Pakkeforløp for prostatakreft. https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-prostatakreft. Accessed Oct 2018

30.

Skyrud KD, Bray F, Moller B (2014) A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer 135(1):196–203. https://doi.org/10.1002/ijc.28645 CrossRefPubMed

Title: Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
Authors: Kirsti Aas
Sophie Dorothea Fosså
Rune Kvåle
Bjørn Møller
Tor Åge Myklebust
Ljiljana Vlatkovic
Stig Müller
Viktor Berge
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2570-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Systematic review and cumulative analysis of the managements for proximal impacted ureteral stones

Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes

Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study

Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia

Long-term follow-up after cystectomy for bladder pain syndrome: pain status, sexual function and quality of life

Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?